EN
SINOVAC Addresses COVID-19 Mutations with Broad-Spectrum Neutralizing Antibody Products: SA55 Injection and Nasal Spray Approved for Clinical Trial in China
May 29, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced its Anti-COVID-19 Antibody SA55 for Injection, which is intended for the treatment of COVID-19 infections, was approved on May 24 for clinical trial in China.
This follows the National Medical Products Administration's approval in April for the clinical trial of the use of the SA55 Nasal Spray in the prevention of COVID-19 infections.
To effectively combat the constantly mutating strains of the novel coronavirus, SINOVAC has been developing several broad-spectrum neutralizing antibody products, including Anti-COVID-19 Antibody SA55 for Injection and SA55 Nasal Spray.
The broad-spectrum neutralizing antibody SA55 was founded by a research team led by Dr. Yunlong Cao, researcher at Peking University’s Biomedical Pioneering Innovation Center. Based on high-throughput epitope determination, the team proposed that broad neutralizing antibody therapies should target non-immunodominant epitopes within the receptor-binding domain to circumvent escape mutations driven by herd-immunity. SA55 was discovered within a large repertoire of broad-spectrum sarbecovirus neutralizing antibodies found in individuals who had recovered from SARS and were subsequently vaccinated against SARS-CoV-21. Further studies underscore the efficacy of SA55 in neutralizing the omicron variant and its sublineages, such as XBB, XBB.1, and XBB.1.52.
"SA55 is almost absent in the current population immunity and is currently the only antibody in clinical development that is effective against all known circulating strains of the novel coronavirus," said Dr. Yunlong Cao, during a recent interview with Science and Technology Daily.
The injection can be used to treat and prevent severe cases, which is particularly useful to elderly and immunocompromised individuals, or those ineligible for vaccination or with poor immune responses, he added.
With these latest approvals, SINOVAC will start clinical trials for the injection and nasal spray forms of the neutralizing antibody SA55. By leveraging its extensive experience in COVID-19 vaccine development and production, SINOVAC is capable of large-scale manufacture of these broad-spectrum neutralizing antibody products in compliance with Good Manufacturing Practice standards.
To date, more than 2.9 billion doses of SINOVAC’s COVID-19 vaccine, CoronaVac®, have been shipped globally, making the Company one of the biggest COVID-19 vaccine manufactures in the world.
References:
1.Cao, Yulong, et al. "Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents." Cell reports 41.12 (2022): 111845.
2.Yue, Can et al. “ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.” The Lancet. Infectious diseases vol. 23,3 (2023): 278-280. doi:10.1016/S1473-3099(23)00010-5
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.